ARS Pharmaceuticals, Inc.
SPRY
$8.54
$0.526.48%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 200.97M | 244.99M | 288.21M | 240.13M | 275.73M |
| Total Receivables | 29.46M | 26.35M | 37.69M | 26.08M | 10.27M |
| Inventory | 8.82M | 8.37M | 7.78M | 8.74M | 7.27M |
| Prepaid Expenses | 5.99M | 5.19M | 3.83M | 4.46M | 9.63M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | -- | -- | 1.35M | 2.03M | 963.00K |
| Total Current Assets | 245.24M | 284.90M | 338.86M | 281.44M | 303.86M |
|
|
|||||
| Total Current Assets | 245.24M | 284.90M | 338.86M | 281.44M | 303.86M |
| Net Property, Plant & Equipment | 2.29M | 2.47M | 2.65M | 2.64M | 1.15M |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | 14.18M | 14.45M | 14.85M | 13.16M | 7.49M |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 25.87M | 25.84M | 16.44M | 16.24M | 14.82M |
| Total Assets | 287.57M | 327.65M | 372.80M | 313.47M | 327.32M |
|
|
|||||
| Total Accounts Payable | 4.80M | 9.16M | 8.38M | 16.10M | 8.32M |
| Total Accrued Expenses | 22.26M | 10.05M | 24.15M | 10.68M | 10.33M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | -- | -- | 583.00K | 589.00K | 73.00K |
| Total Finance Division Other Current Liabilities | 22.55M | 19.94M | 17.77M | 18.23M | 8.90M |
| Total Other Current Liabilities | 22.55M | 19.94M | 17.77M | 18.23M | 8.90M |
| Total Current Liabilities | 49.61M | 39.15M | 50.88M | 45.60M | 27.62M |
|
|
|||||
| Total Current Liabilities | 49.61M | 39.15M | 50.88M | 45.60M | 27.62M |
| Long-Term Debt | 171.20M | 168.51M | 168.27M | 71.96M | 69.38M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | -- | -- | 949.00K | 1.07M | -- |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 5.46M | 5.74M | 5.05M | 2.52M | 1.34M |
| Total Liabilities | 226.26M | 213.39M | 225.15M | 121.15M | 98.34M |
|
|
|||||
| Common Stock & APIC | 416.63M | 408.74M | 400.94M | 394.50M | 386.15M |
| Retained Earnings | -355.22M | -294.60M | -253.28M | -202.13M | -157.25M |
| Treasury Stock & Other | -96.00K | 125.00K | -7.00K | -46.00K | 72.00K |
| Total Common Equity | 61.31M | 114.26M | 147.66M | 192.32M | 228.97M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 61.31M | 114.26M | 147.66M | 192.32M | 228.97M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 61.31M | 114.26M | 147.66M | 192.32M | 228.97M |
|
|
|||||